A failure of Lipocine Inc.'s Tlando (testosterone undecanoate) to meet any of its three pre-specified maximal serum testosterone concentrations (Cmax) secondary endpoints highlights a series of issues the testosterone replacement therapy will have to overcome in front of a US FDA panel in its quest for approval.
The agency's Bone, Reproductive, and Urologic Drugs Advisory Committee will convene Jan. 10 to discuss a slew of safety issues...




